Please assess the completion status of the following clinical trial:

Trial Title: (ARTEMIS-IPF) Randomized, Placebo-Controlled Study to Evaluate Safety and Effectiveness of Ambrisentan in IPF

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or females from 40 to 80 years of age~* Diagnosis of IPF~* Honeycombing (fibrosis in the lung) on high-resolution computerised tomography (HRCT) scan of less than or equal to 5%~* Willing and able to have 2 right heart catheterizations performed~* Willing to have monthly lab tests to monitor liver function~* Able to perform the 6 minute walk test (indicated adequate physical function)~* Must have meet lung function requirements~* Normal liver function tests~* Negative serum pregnancy test~* Willing to use at least 2 reliable methods of contraception~* Able to understand and willing to sign informed consent form~Exclusion Criteria:~* No restrictive lung disease (other than usual interstitial pneumonia or IPF)~* No obstructive lung disease~* No recent or active respiratory exacerbations~* No recent hospitalization for an IPF exacerbation~* No recent history of alcohol abuse~* Chronic sildenafil (or same drug class) use for pulmonary hypertension~* Chronic treatment with certain medications for IPF within 30 days of randomization~* No other serious medical conditions

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Ambrisentan (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).